Hueber, Wolfgang
Novartis (Switzerland) · Novartis Institutes for BioMedical Research
3 papers on CoChat
Most cited papers
- Verified
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut
Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis
Cited by 1,547
- Verified
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine
Psoriasis: Treatment and PathogenesisRheumatoid Arthritis Research and Therapies
Cited by 860
- Verified
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., et al. (2014) · Annals of the Rheumatic Diseases
Spondyloarthritis Studies and TreatmentsPsoriasis: Treatment and Pathogenesis
Cited by 343
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free